Danaher (DHR) Earnings Date & Reports

Key Takeaways

• Reported revenue of $6.3 billion, up 5.5% year-over-year.
• Non-GAAP adjusted diluted EPS reached $1.94, exceeding consensus estimates of $1.84 and rising 8.0% from the prior year.
• GAAP net earnings totaled $870 million, or $1.23 per diluted share, up significantly year-over-year.
• Non-GAAP core revenue grew 3.0% year-over-year, with underlying trends excluding respiratory testing improving to 4.5%.
• Company raised full-year 2026 adjusted diluted EPS guidance to $8.45–$8.60 from the prior range of $8.35–$8.55.
• Life Sciences segment showed strongest performance in several quarters, supported by solid order trends in bioprocessing.

Earnings Context and Why It Matters

Danaher Corporation, a global leader in life sciences and diagnostics, delivers quarterly results that offer critical insights into demand for scientific and clinical tools amid ongoing industry recovery. The second quarter often reflects seasonal patterns in customer project timing and end-market spending. Strong performance here can signal improving bioprocessing and diagnostics trends, which are key drivers for the company’s long-term growth. Investors closely monitor these reports for guidance updates that shape expectations for the remainder of the fiscal year.

Reported Results

Danaher reported second quarter 2026 revenue of $6.3 billion, a 5.5% increase from the year-ago period. Non-GAAP core revenue rose 3.0% year-over-year, while core revenue excluding respiratory testing revenue advanced 4.5%. Non-GAAP adjusted diluted earnings per share climbed 8.0% to $1.94, surpassing analyst consensus estimates of $1.84. GAAP net earnings reached $870 million, or $1.23 per diluted share.

Operating cash flow totaled $1.5 billion, with non-GAAP free cash flow at $1.3 billion. The company highlighted stronger-than-expected results driven by Life Sciences momentum and disciplined execution. Earlier-than-anticipated completion of the Masimo acquisition contributed to the raised full-year outlook.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. AI Screener

Market Reaction and Investor Sentiment

Following the July 21, 2026 release, investor focus centered on the EPS beat and the upward revision to full-year guidance. The results reflected improving core growth trends and positive commentary on end-market recovery. Analysts noted the company’s ability to deliver high-single-digit adjusted EPS growth despite project timing impacts in bioprocessing, supporting a constructive near-term sentiment.

Forward Outlook and Key Factors to Monitor

Danaher raised its full-year 2026 adjusted diluted EPS guidance to a range of $8.45 to $8.60. The company expects non-GAAP core revenue growth of 3.0% to 4.0% for the full year and 2.0% to 3.0% in the third quarter.

Management highlighted continued end-market recovery and traction from growth initiatives as supporting an exit from 2026 at a mid-single-digit core revenue growth rate. Key areas to watch include bioprocessing order trends, which grew mid-teens in the quarter, and the integration of the Masimo acquisition.

Investors should also monitor foreign currency impacts, customer project timing in Life Sciences, and any updates on broader industry demand signals in diagnostics and life sciences tools. Margin performance and cash flow generation will remain important indicators of operational execution.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations